Form 4: Rhythm Pharmaceuticals Director Granted Equity Awards Valued at Over $700,000

Rhythm Pharmaceuticals, Inc. director David W.J. McGirr was granted 7,037 stock options and 4,712 restricted stock units as part of his compensation, vesting in 2026.

Summary

• David W.J. McGirr, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), received new equity awards on June 24, 2025.
• The awards include 7,037 stock options with an exercise price of $63.66 per share.
• These stock options become exercisable upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, and are set to expire on June 23, 2035.
• Mr. McGirr also received 4,712 Restricted Stock Units (RSUs), where each unit represents a contingent right to receive one share of the Issuer's common stock.
• Both the stock options and RSUs are subject to full vesting upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders to be held in 2026, provided Mr. McGirr continues his service on such vesting date.

Sentiment

Score: 5

Explanation: A routine Form 4 filing disclosing an equity grant to a director is generally neutral, reflecting standard compensation practices rather than significant positive or negative operational news.

Positives

• The granting of equity awards to a director helps align their financial interests with those of the company's shareholders, encouraging long-term value creation.
• The vesting conditions, tied to continued service, incentivize the director's ongoing commitment and contribution to the company.

Risks

• The ultimate value realized from the granted stock options and restricted stock units is directly dependent on the future performance and market price of Rhythm Pharmaceuticals' common stock.
• Unvested awards would be forfeited if the director's service to the company ceases before the specified vesting dates.

Future Outlook

The document indicates future vesting events for the granted equity awards, contingent on the director's continued service through June 24, 2026, or the date of the Issuer's next annual meeting in 2026.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice across industries to align executive and board member incentives with shareholder interests. Such grants are standard components of compensation packages in the biotechnology and pharmaceutical sectors, like Rhythm Pharmaceuticals, Inc., aiming to retain talent and encourage long-term value creation.

Comparison to Industry Standards

• Equity grants to directors, including stock options and restricted stock units, are a standard component of compensation packages in the biotechnology and pharmaceutical industries.
• While specific grant sizes vary based on company size, performance, and individual roles, the structure of these awards, with vesting periods tied to continued service, aligns with common corporate governance practices seen in comparable companies within the sector.
• No specific comparable companies, projects, or numerical results are mentioned in the document to allow for a direct quantitative comparison.

Related Party Transactions

• The grant of stock options and restricted stock units to David W.J. McGirr, a director of Rhythm Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of equity awards, while potentially leading to minor dilution upon vesting and exercise, is intended to align the director's interests with long-term shareholder value creation.
• Employees: While this specific filing pertains to a director, equity compensation is a common incentive tool that can indirectly influence overall employee compensation strategies and morale within the company.

Next Steps

• The stock options and restricted stock units are scheduled to vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, subject to continued service.
• The granted stock options will expire on June 23, 2035.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, stock options, restricted stock units, RSUs, equity grant, insider transaction, director compensation, David W.J. McGirr